ESPAUR report 2025 to 2026: Foreword
Published 12 November 2026
Antimicrobial resistance (AMR) occurs when pathogens evade the action of the drugs that have been developed to counter them. AMR remains one of the most significant global threats to human health and to the sustainability of modern medicine. An estimated 4.71 million deaths were associated with bacterial AMR globally in 2021 with this predicted to increase to 8.22 million by 2050 (1). As well as long-term consequences to population health, AMR also has immediate consequences at an individual level as, by increasing risk of treatment failure, AMR is associated with re-consultation, emergency department attendance, hospital admission, extended length-of-stay and increased morbidity and mortality.
Several factors accelerate the development of AMR, including the misuse and overuse of antimicrobials. Earlier this year, member states at the 79th World Health Assembly adopted the updated Global Action Plan on Antimicrobial Resistance (GAP-AMR) 2026 to 2036 (2). The 10-year plan aims to reduce the global burden of AMR by preventing infections and ensuring continuous access to effective treatments. Key updates to the plan included a stronger focus on preventing infections through improved water and sanitation, and biosecurity, new targets set with a goal to reduce bacterial AMR-associated deaths by 10% globally by 2030, and an expanded scope with an additional sixth strategic objective dedicated entirely to governance, sustainable financing and accountability (3).
One of the pillars of the UK Health Security Agency’s (UKHSA) mission is preparing and responding to threats posed by infectious diseases, including the emergence of AMR, to reduce their impact. The collection of data to monitor trends in resistant pathogens and associated infections, as well as in the consumption of antimicrobials, is crucial to the UKHSA’s goals. Having robust data enables informed decisions about where resources should be focused and how interventions are best directed for those disproportionately affected by the burden of AMR.
To take effective action, it is crucial that data pertinent to AMR is accessible to all in a format that allows action to be taken – whether by policymakers or healthcare professionals who need such data to inform their research or response, or the public so that they can make decisions important to each one of them in their daily lives.
Publication of the annual ESPAUR report offers a comprehensive analysis of temporal trends in both the prevalence of infections caused by resistant pathogens and levels of antimicrobial prescribing in England. The number of antibiotic-resistant infections has risen by 16.8% since 2019, driven primarily by Escherichia coli and Klebsiella pneumoniae. However, the burden and impact of infectious disease continue to persist by age, deprivation, geographical area and ethnicity. For example, the gap between the most and least deprived quintiles has widened since 2019 (29%) and remained substantially elevated in 2025 (44.2%). Resistant infections, including those by carbapenemase-producing organisms and fungal bloodstream infections continue to rise, reinforcing the need for targeted surveillance, stewardship and prevention measures aligned with the 2024-to-2029 UK AMR National Action Plan.
Antimicrobial stewardship, professional education, training and public engagement initiatives are also covered in this report. Activities aimed at improving antimicrobial use and management include the TARGET (Treat Antibiotics Responsibly, Guidance Education and Tools) toolkit, the new UK-adapted AWaRe (Access, Watch and Reserve) categories of antibiotics, World AMR Awareness Week, the Antibiotic Guardian campaign and e-Bug. The report also presents an overview of a broad range of new and ongoing research projects in healthcare-associated infections and AMR that were conducted by UKHSA with academic partners, many of whom contribute to key objectives set out in the 2024-to-2029 UK National Action Plan for AMR.
England continues to reduce and optimise antibiotic use, but AMR is still increasing, particularly among Gram-negative bloodstream infections, and the burden is increasingly concentrated in older people, vulnerable populations and deprived communities. Health inequalities are one of the strongest and most consistent findings across resistance, infection burden and antimicrobial use, supporting the need for more targeted interventions.
Finally, this report also contains information on actions being taken by ESPAUR’s contributors and audience to combat the rise of AMR and improve antimicrobial prescribing. Our considerable thanks to all our contributing stakeholders whose broad breadth of work and activities not only make up this report but influence policy in the face of the global health threat we are facing in AMR.
References
-
Global Burden of Disease 2021 Antimicrobial Resistance Collaborators. ‘Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050’ Lancet 2024: volume 404, issue 10,459, pages 1,199 to 191,226
-
‘The World Health Assembly adopts updated Global Action Plan on Antimicrobial Resistance (2026-2036)’ [press release] 2026
-
World Health Organization. Draft updated global action plan on antimicrobial resistance 2026-2036 2026